Lyle Hohnke

Lyle Hohnke joined TD in 1994 and has over 35 years of health care industry experience, focusing on biotechnology, pharmaceuticals and medical devices. He has specific expertise in identifying and evaluating the commercial possibilities of new technologies, and in the technology transfer process. Lyle has demonstrated success in establishing proprietary deal flow and assessing the needs and realities of small venture-stage companies.

Prior to TD, Lyle was a general partner of an Iowa-based venture capital fund, where he led a leveraged buyout of a division of Bayer A.G., becoming chairman and chief executive officer of Diamond Animal Health. Previously, he served as vice president for research at the University of Connecticut Health Center where he managed nine core research facilities and supervised the patent and licensing process. Lyle played an integral role in leading the university into the development field as president of the University of Connecticut Research and Development Corporation, and later directed a state effort to establish a venture capital fund with state and corporate funding.

Lyle serves on the boards of several public and private companies. He has a BA from Western Michigan University and an MA/PhD from the University of Oregon. He was a postdoctoral fellow at the UCLA School of Medicine and received an MBA from the Hartford Graduate Center/RPI.